Report to highlight N.J. drugmakers' progress in fight against cancer

Trenton, NJ - According to Anjalee Khemlani of NJBiz, "A number of major New Jersey pharmaceutical companies are being monitored for progress on cancer cures. A report set to be released next Wednesday names more than 30 companies, including major players like Merck, Bristol-Myers Squibb, Novartis and Sanofi US."

The 146-page listing of all companies in the U.S. or working with U.S. firms highlights the ongoing push to kill America’s biggest killer.

This year, more than 1.6 million new cancer cases will be diagnosed, and almost 600,000 Americans will die from a form of the disease, according to the Pharmaceutical Research and Manufacturers of America, which released the report.

“The oncology research community has made significant advances in identifying new, more effective therapies to help people with cancer achieve positive treatment outcomes and transition from being cancer patients to cancer survivors,” said John Castellani, CEO and president of PhRMA. “However, the battle is far from over.”

The drugs listed in the report are in one of the various stages including development, awaiting approval from the Food and Drug Administration or in clinical trials.

More than 70 percent of the 836 medicines in the pipeline have the potential to be personalized medicine, according to PhRMA.

Since the early 1990s, cancer survival rates have increased 22 percent.

Pharma companies in New Jersey with medicines in the pipeline include:

·         AB Science USA

·         Advaxis

·         Allergan

·         Arno Therapeutics

·         Asana BioSciences

·         Bayer HealthCare Pharmaceuticals

·         Belrose Pharma

·         Bristol-Myers Squibb

·         Celgene

·         Celator Pharmaceuticals

·         CellDex Therapeutics

·         Celsion

·         Cornerstone Pharmaceuticals

·         Cyclacel Pharmaceuticals

·         Daiichi Sankyo

·         Eagle Pharmaceuticals

·         Eisai

·         Immunomedics

·         InnoPharma

·         Janssen Research & Development

·         Kyowa Hakko Kirin

·         Merck

·         Novartis

·         Nymox Pharmaceutical

·         PDS Biotechnology

·         PTC Therapeutics

·         Sanofi US

·         Soligenix

·         Taiho Oncology

·         Vicus Therapeutics

·         XEME Biopharma

For more on the report, click here.